SIMCERE PHARMA (HK.2096) to host 2022 R&D Day
HONG KONG, April 7, 2022 /PRNewswire/ -- SIMCERE PHARMA (HK.2096), an innovation and R&D-driven pharmaceutical company with a mission of "providing today's patients with medicines of the future", will host a virtual R&D Day, on Friday, 15 April, 2022, at 21:00-23:00 (HKT) / 9:00-11:00 (EST) / 13:00-15:00 (GMT). SIMCERE PHARMA 2022 R&D DAY AGENDA The R&D Day will feature...
REDCLOUD BIO TO PRESENT PRECLINICAL DATA OF NEXT-GENERATION EGFR TKI H002 AT ANNUAL MEETING OF AMERICAN ASSOCIATION OF CANCER RESEARCH
SHANGHAI, April 7, 2022 /PRNewswire/ -- RedCloud Bio (the "Company"), an innovative biotech company integrating structural pharmacology and computational approaches to advance small molecule drug development, announced the upcoming presentation of preclinical data of H002, a next-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in non-small cell lung cancer (NSCLC). The data will be presented at...
Contract Development and Manufacturing Organizations Shifting Focus to Meet Future Demand
An integrated and agile approach enables the pharmaceutical CDMO industry to simplify manufacturing as it moves from primary care medicines to specialty medicines SAN ANTONIO, April 7, 2022 /PRNewswire/ -- Transformational forces are influencing the global contract development and manufacturing organization (CDMO) market's growth. Disruptive, innovative business models and technologies mandate the need to commercialize personalized therapies and focus...
Asset Visibility Market Opportunity in the Pharmaceutical Industry Worth US$2.7 Billion by 2026
IoT technologies contribute to rapidly expanding market for safeguarding goods as well as improving enterprises' bottom line LONDON, April 7, 2022 /PRNewswire/ -- Pharmaceutical manufacturers, distributors, and transportation providers all face unique pain points within their supply chain operations. Product worth US$30 billion is damaged each year, and companies in the pharmaceutical...
Therapy Pro wins at the 2022 Australian Disability Service Awards
Therapy Pro has been recognised at the Australian Disability Service Awards for their innovative program offerings and positive exceptional outcomes. Claiming "Best Early Intervention Program", the award was received by Managing Director Phil Laidlaw. The Australian Disability Awards saw industry leaders gather in Sydney for the event, hosted by paralympian medallists, Christie Dawes and Don Elgin,...
Rona Therapeutics Announces Completion of $33 Million Series A Financing to Advance Global Discovery and Development of RNA Therapeutics
- Funding from long-term investors to build leading delivery platform and scalable drug discovery engine to enable modular and programmable medicines - Company is harnessing the potential of RNA therapeutics to deliver medicines to liver and extrahepatic tissues with specific, stable and prolonged effects SHANGHAI, April 7, 2022 /PRNewswire/ -- Rona Therapeutics, a fully integrated platform company dedicated to...
Psychobiotic PS128 Registration, Health Claims Approved in Thailand, Canada
TAIPEI, April 7, 2022 /PRNewswire/ -- Bened Biomedical announced recent approval of the company's probiotic L. plantarum PS128 in Thailand and Canada. Authorities in each country also endorsed health claims that may be made about the strain. Local distributors will launch PS128 products this year. "It's inspiring to know that 100...
BIO KOREA, Asia’s Biggest Bio-Health Convention, to Open in May 2022
Global Event to Kick off as the Post-COVID Era Begins in Earnest, with Theme "Beyond the Pandemic, into a Next Wave" SEOUL, South Korea, April 7, 2022 /PRNewswire/ --Initiated in 2006, BIO KOREA is the biggest bio-health convention in Asia that is dedicated to promoting the international standing of Korea's healthcare industry and ensuring the industry's sustainable growth. BIO...
Alterity Therapeutics Announces Presentation of bioMUSE Data at the American Academy of Neurology (AAN) Annual Meeting
The data provides further validation of the intended Phase 2 study design MELBOURNE, Australia and SAN FRANCISCO, April 7, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that new data are being...
Harbour BioMed Announces Global Out-License Agreement with AstraZeneca for CLDN18.2xCD3 Bispecific Antibody HBM7022
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, April 7, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", "the Company", HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics, today announced a global out-license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) for CLDN18.2xCD3 bispecific antibody (HBM7022), a novel bispecific antibody generated from...
